Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome

• ClinicalTrials.gov Identifier: NCT02670525
• Recruitment Status: Active, not recruiting
• First Posted: February 1, 2016
• Results First Posted: July 18, 2023
• Last Update Posted: May 8, 2024
• Sponsor: Dana-Farber Cancer Institute
• Information provided by (Responsible Party): Yana Pikman, MD, Dana-Farber Cancer Institute

Tracking Information

• First Submitted Date: January 28, 2016
• First Posted Date: February 1, 2016
• Results First Submitted Date: May 15, 2023
• Results First Posted Date: July 18, 2023
• Last Update Posted Date: May 8, 2024
• Actual Study Start Date: August 17, 2016
• Actual Primary Completion Date: May 16, 2022 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: June 29, 2023)

Rate of Patients With Actionable Alterations [ Time Frame: Actionable alteration was identified based on a combination of fluorescence in situ hybridization (FISH)/cytogenetics and sequencing. Average time to full results was 2 weeks. ]

An actionable alteration was defined as a cancer-associated genomic event for which there was a targeted drug available. Actionable genetic alterations were identified by a combination of standard-of-care cytogenetics/fluorescence in situ hybridization (FISH) and sequencing performed as part of the study. This study is considered feasible if at least 13% of participants analyzed have profile data and identifiable actionable alterations. A 90% exact binomial confidence interval is presented for the rate of patients with actionable alterations to compare the observed rate against 13%.

• Original Primary Outcome Measures (submitted: January 29, 2016): Rate of patients with actionable alterations [ Time Frame: 2 Years ]

Current Secondary Outcome Measures (submitted: June 29, 2023)

• Rate of Somatic Genomic Alterations [ Time Frame: 2 Years ]
  This Secondary Outcome will be addressed by describing the somatic genomic alterations in Cohort 1 (Relapsed/Refractory Leukemia arm) and Cohort 2 (New Diagnosis arm) that are discovered by genomic analyses.
• Rate of Results Reporting [ Time Frame: 2 Years ]
  This Secondary Outcome will be addressed by a description of the time of results reporting. Documentation of the time of sample receipt and processing, resources and personnel utilized at each step of the process, time to results reporting, interpretation and review by Expert panel and communication of results to the primary oncologist will be captured.
• Parent's Feelings and Understanding of Genomic Testing [ Time Frame: 2 Years ]
  This Secondary Outcome will be addressed by describing the hopes and concerns of parents of children with recurrent/refractory/high-risk de novo leukemia regarding genomic testing of their child's leukemia as well as their understanding of the testing and evaluate whether the hopes and concerns were realized following the return of results.
• Analysis of Primary Leukemia Sensitivity Testing and Establishment of Xenograft Models [ Time Frame: 2 Years ]
  This Secondary Outcome will be addressed by completing analysis of the primary leukemia sensitivity testing to a panel of drugs or shRNA and establishing xenograft models in dedicated participating research laboratories and conducting co-clinical trials with the recommended matched therapy once the animal model is established.

Original Secondary Outcome Measures (submitted: January 29, 2016)

• Rate of Somatic genomic alterations [ Time Frame: 2 Years ]
• Rate of Results Reporting [ Time Frame: 2 Years ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome
• Official Title: Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome

Brief Summary

This research study is seeking to gain new knowledge about Recurrent, Refractory, or High Risk Leukemias in children and young adults.

This study is evaluating the use of specialized testing called leukemia profiling. Once the profiling is performed, the results are evaluated by an expert panel of physicians, scientists and pharmacists. This may result in a recommendation for a specific cancer therapy or a clinical trial called matched targeted therapy (MTT). The results of the leukemia profiling and, if applicable, the MTT recommendation will be communicated to the participant's primary oncologist.

Detailed Description

Our tissues and organs are made up of cells. Cancer occurs when the molecules that normally control cell growth are damaged. The damage results in unchecked cell growth which causes a tumor, a collection of cancer cells. The damage is referred to as an alteration. There are different types of cancer-causing alterations. Genes are the part of cells that contain the instructions which tell our cells how to make the right proteins to grow and work. Genes are composed of Deoxyribonucleic Acid (DNA) letters that spell out these instructions.

By participating in this study, the participant's leukemia cells will be tested for cancer causing alterations. This testing is called leukemia profiling. The leukemia profiling will be performed using bone marrow or blood that has already been obtained during a clinical test. Alternately, the profiling may be done on leukemia cells that are planned to be obtained as part of routine clinical care.

This study will determine whether it is possible to use profiling results to determine a matched targeted therapy for patients with leukemia. It will describe the range of mutations found in patients with leukemia with this type of profiling, and describe the clinical outcomes of patients who receive a matched targeted therapy.

• Study Type: Interventional
• Study Phase: Not Applicable
• Study Design: Allocation: Non-Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Diagnostic

Condition

• Recurrent, Refractory, or High Risk Leukemias
• Matched Targeted Therapy

Intervention

Genetic: Leukemia Profiling

Genetic profiling of leukemia cells will be performed and analyzed by an expert panel. Matched targeted therapy recommendation based on profiling results will be made if available. The recommendation, if available, will be communicated to the primary oncologist.

Study Arms

• Experimental: Relapsed/Refractory Leukemia

  Cohort 1: Relapsed/Refractory Leukemia

  • Acute lymphoblastic leukemia (ALL), first or greater relapse
  • Acute myeloid leukemia (AML), first or greater relapse
  • Leukemia refractory to induction chemotherapy
  • Other recurrent leukemia
  • Myelodysplastic syndrome (MDS), first or greater relapse, or refractory to initial therapy

  After the screening procedures confirms patient eligibility:

  • Leukemia Profiling will be performed
  • Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation.
  Intervention: Genetic: Leukemia Profiling
• Experimental: New Diagnosis

  Cohort 2: New Diagnosis

  • Acute myeloid leukemia (AML), new diagnosis (excluding acute promyelocytic leukemia (APL))
  • New diagnosis infant mixed-lineage leukemia (MLL)-rearranged ALL or low hypodiploid (<40 chromosomes) ALL
  • Rare leukemia- e.g., juvenile myelomonocytic leukemia (JMML), leukemia of ambiguous lineage
  • Secondary leukemia
  • Myelodysplastic syndrome (MDS) not eligible for stem cell transplant

  After the screening procedures confirms eligibility:

  • Leukemia Profiling will be performed
  • Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation.
  Intervention: Genetic: Leukemia Profiling

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: May 27, 2022): 338
• Original Estimated Enrollment (submitted: January 29, 2016): 200
• Estimated Study Completion Date: May 2027
• Actual Primary Completion Date: May 16, 2022 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Birth to ≤ 30 years at study entry
• Diagnosis: Patients will be enrolled in one of the two cohorts based on diagnosis:

Cohort 1: Relapsed/refractory leukemia

• Acute lymphoblastic leukemia (ALL), first or greater relapse
• Acute myeloid leukemia (AML), first or greater relapse
• Leukemia refractory to induction chemotherapy
• Other recurrent leukemia
• Myelodysplastic syndrome (MDS), first or greater relapse, or refractory to initial therapy

Cohort 2: New diagnosis

• Acute myeloid leukemia (AML), new diagnosis
• New diagnosis infant mixed-lineage leukemia (MLL)-rearranged ALL or low hypodiploid (<40 chromosomes) ALL
• Rare leukemia- e.g., juvenile myelomonocytic leukemia (JMML), leukemia of ambiguous lineage
• Secondary leukemia
• Myelodysplastic syndrome (MDS) not eligible for stem cell transplant

Pathologic Criteria

• Histologic confirmation of leukemia at the time of diagnosis or recurrence

Specimen Samples

• Sufficient leukemia specimen available for profiling from diagnosis or recurrence OR bone marrow aspirate/blood draw/pheresis/other fresh sample of patient leukemia cells planned for clinical care anticipated to allow collection of minimum specimen for testing.

Exclusion Criteria:

• Insufficient leukemia specimen available for profiling from diagnosis or recurrence; or bone marrow evaluation/blood draw/other leukemia cell sample NOT planned to be obtained for clinical care; or peripheral blast percentage <20% AND clinical blood draw not planned.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: up to 30 Years (Child, Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT02670525
• Other Study ID Numbers: 15-384
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Yana Pikman, MD, Dana-Farber Cancer Institute
• Original Responsible Party: Same as current
• Current Study Sponsor: Dana-Farber Cancer Institute
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Yana Pikman, MD; Dana-Farber Cancer Institute

• PRS Account: Dana-Farber Cancer Institute
• Verification Date: May 2024